BRAF G596V

CI-VAR-00001768Explore in graph →NP_004324.2:p.Gly596ValNM_004333.4:c.1787G>TClinVar 40387 CIViC 1650 rs397507483

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
BRAF G596V	Vemurafenib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4779 In a retrospective study of 35 lung adenocarcinoma patients (chemotherapy previously administered in 86% of patients), a patient harboring a BRAF G596V mutation was associated with partial response to… (full text at CIViC) PMID 26200454 · Gautschi et al., 2015 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.